Make Better Decisions - Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

Get the Book: Make Better Decisions

Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

PDF eBook: Just $10 Get Print Book on Amazon

Serving leading biopharmaceutical companies globally:

McKinsey
Moodys
Dow
McKesson
Medtronic
Baxter

Last Updated: October 23, 2019

DrugPatentWatch Database Preview

TIKOSYN Drug Profile

See Plans and Pricing

« Back to Dashboard

When do Tikosyn patents expire, and when can generic versions of Tikosyn launch?

Tikosyn is a drug marketed by Pfizer and is included in one NDA.

The generic ingredient in TIKOSYN is dofetilide. There are thirteen drug master file entries for this compound. Ten suppliers are listed for this compound. Additional details are available on the dofetilide profile page.

Drug patent expirations by year for TIKOSYN
Drug Prices for TIKOSYN

See drug prices for TIKOSYN

Recent Clinical Trials for TIKOSYN

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
Spaulding Clinical Research LLCPhase 1
Food and Drug Administration (FDA)Phase 1
VA Office of Research and DevelopmentN/A

See all TIKOSYN clinical trials

Recent Litigation for TIKOSYN

Identify potential future generic entrants

District Court Litigation
Case NameDate
Pfizer Inc. v. Aurobindo Pharma USA Inc.2017-12-08
Apicore US LLC v. Pfizer Inc.2016-12-12
Pfizer Inc. v. Tiger Pharmaceuticals, LLC2014-12-11

See all TIKOSYN litigation

Pharmacology for TIKOSYN
Drug ClassAntiarrhythmic
Synonyms for TIKOSYN
(Dofetilide) N-[4-(2-{[2-(4-Methanesulfonylamino-phenyl)-ethyl]-methylamino}-ethoxy)-phenyl]-methanesulfonamide
1-(4-methanesulfonamidophenoxy)-2-(N-(4-methanesulfonamidophenethyl)-N-methylamine)ethane
1-(4-Methanesulphonamidophenoxy)-2-[N-(4-methanesulphonamidophenethyl)-N-methylamino]ethane
1-(4-Methansulphonamidophenoxy)-2-[N-(4-methanesulphonamidophenethyl)-N-methylamino]ethane
1-MSPMPE
115256-11-6
256D116
A803396
AB0004775
AB00639976_09
AB00639976-06
AB00639976-08
AB2000201
AC-385
AC1L2FYH
AC1Q6VUS
ACT04222
AKOS005259921
AN-15862
API0002471
BC660134
BCP04770
BCP0726000009
BCP9000619
BDBM50031720
beta-((p-Methanesulfonamidophenethyl)methylamino)methanesulfono-p-phenetidide
BRD-K86887724-001-05-6
C-22372
C07751
C19H27N3O5S2
CAS-115256-11-6
CC-27363
CCG-101037
CHEBI:4681
CHEMBL473
CPD000466333
CS-2200
CTK8F9356
D00647
DB00204
Dofetilida
Dofetilida [INN-Spanish]
Dofetilide
Dofetilide (JAN/USAN/INN)
Dofetilide (Tikosyn)
Dofetilide [USAN:BAN:INN]
Dofetilide [USAN:USP:INN:BAN]
Dofetilide, >=98% (HPLC)
Dofetilide, United States Pharmacopeia (USP) Reference Standard
Dofetilide;
Dofetilide(Tikosyn)
Dofetilidum
Dofetilidum [INN-Latin]
DSSTox_CID_26433
DSSTox_GSID_46433
DSSTox_RID_81610
DTXSID5046433
FC0019
FT-0631076
GTPL2604
HMS2051N14
HMS2089F03
HMS2232H19
HMS3261G03
HMS3370B18
HMS3393N14
HMS3655A17
HMS3715H20
HSDB 7927
HY-B0232
I06-0340
I881
IXTMWRCNAAVVAI-UHFFFAOYSA-N
J-003271
KB-09147
KS-00000XNN
LS-90151
Methanesulfonamide, N-(4-(2-(methyl(2-(4-((methylsulfonyl)amino)phenoxy)ethyl)amino)ethyl)phenyl)
Methanesulfonamide, N-(4-(2-(methyl(2-(4-((methylsulfonyl)amino)phenoxy)ethyl)amino)ethyl)phenyl)-
MFCD00869707
MLS000759442
MLS001424185
MLS006010154
MolPort-003-847-012
MRF-0000317
N-(4-(2-(methyl(2-(4-(methylsulfonamido)phenoxy)ethyl)amino)ethyl)phenyl)methanesulfonamide
n-(4-(2-{2-(4-(methanesulphonamido)phenoxyl)-n-methylethylamino}ethyl)phenyl)-methanesulphonamide
N-(4-{2-[methyl(2-{4-[(methylsulfonyl)amino]phenoxy}ethyl)amino]ethyl}phenyl)methanesulfonamide
N-[4-(2-{[2-(4-methanesulfonamidophenoxy)ethyl](methyl)amino}ethyl)phenyl]methanesulfonamide
N-[4-(2-{[2-(4-methanesulfonylamino-phenoxy)-ethyl]-methyl-amino}-ethyl)-phenyl]-methanesulfonamide
N-[4-(2-{[2-(4-Methanesulfonylamino-phenyl)-ethyl]-methyl-amino}-ethoxy)-phenyl]-methanesulfonamide (dofetilide)
N-[4-(2-{[2-(4-Methanesulfonylamino-phenyl)-ethyl]-methyl-amino}-ethoxy)-phenyl]-methanesulfonamide (UK-68798)
N-[4-(2-{[2-(4-METHANESULFONYLAMINO-PHENYL)-ETHYL]-METHYL-AMINO}-ETHOXY)-PHENYL]-METHANESULFONAMIDE DOFETILIDE
N-[4-(2-{2-[4-(methanesulphonamido)phenoxyl]-N-methylethylamino}ethyl)phenyl]-methanesulphonamide
N-[4-[2-[2-(4-methanesulfonamidophenyl)ethyl-methylamino]ethoxy]phenyl]methanesulfonamide
N-[4-[2-[2-[4-(methanesulfonamido)phenoxy]ethyl-methyl-amino]ethyl]phenyl]methanesulfonamide
N-[4-[2-[2-[4-(methanesulfonamido)phenoxy]ethyl-methylamino]ethyl]phenyl]methanesulfonamide
N-[4-[2-[methyl-[2-[4-(methylsulfonylamino)phenoxy]ethyl]amino]ethyl]phenyl]methanesulfonamide
N-[4-[2-[Methyl[2-[4-[(methylsulfonyl)amino]phenoxy]ethyl]amino]ethyl]phenyl]methanesulfonamide
NC00287
NCGC00164549-01
NCGC00164549-02
NCGC00261036-01
R4Z9X1N2ND
s1658
SAM001246621
SC-76467
SCHEMBL16135
SMR000466333
SR-01000759368
SR-01000759368-4
ST24046670
SW197667-2
Tikosyn (TN)
Tikosyn;UK68798
TL8000450
Tox21_112178
Tox21_112178_1
Tox21_500351
UK 68,798
UK 68789
UK 68798
UK-68,798
UK-68798
UK68789
UK68798
UNII-R4Z9X1N2ND
Xelide
ZINC596731

US Patents and Regulatory Information for TIKOSYN

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Pfizer TIKOSYN dofetilide CAPSULE;ORAL 020931-001 Oct 1, 1999 AB RX Yes No   Start Trial   Start Trial   Start Trial
Pfizer TIKOSYN dofetilide CAPSULE;ORAL 020931-002 Oct 1, 1999 AB RX Yes No   Start Trial   Start Trial   Start Trial
Pfizer TIKOSYN dofetilide CAPSULE;ORAL 020931-003 Oct 1, 1999 AB RX Yes Yes   Start Trial   Start Trial   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Expired US Patents for TIKOSYN

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Pfizer TIKOSYN dofetilide CAPSULE;ORAL 020931-001 Oct 1, 1999   Start Trial   Start Trial
Pfizer TIKOSYN dofetilide CAPSULE;ORAL 020931-003 Oct 1, 1999   Start Trial   Start Trial
Pfizer TIKOSYN dofetilide CAPSULE;ORAL 020931-002 Oct 1, 1999   Start Trial   Start Trial
Pfizer TIKOSYN dofetilide CAPSULE;ORAL 020931-003 Oct 1, 1999   Start Trial   Start Trial
Pfizer TIKOSYN dofetilide CAPSULE;ORAL 020931-001 Oct 1, 1999   Start Trial   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >Patent No. >Patent Expiration
Paragraph IV (Patent) Challenges for TIKOSYN
Drugname Dosage Strength RLD Date
➤ Subscribe Capsules 0.125 mg, 0.25 mg, and 0.5 mg ➤ Subscribe   Start Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Merck
Boehringer Ingelheim
Dow
Moodys
Express Scripts
Mallinckrodt

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.